Table 1.

CIC inhibitors

Compound (developer)	Potency in biochemical assays	Indication and/or preclinical effects	Refs
Preclinical stage inhibitors
Benzenetricarboxylate	Ki: 0.07–0.16 mM	Decreased triglyceride synthesis, reduced glucose-stimulated insulin secretion and inhibited cancer cell growth	126,127,132
CPTI-1 (Rosalind Franklin University of Medicine and Science, USA)	Ki: 0.048–0.07 mM	Reduced inflammation and inhibited cancer cell growth	43,128
CPTI-2 (Lombardi Comprehensive Cancer Center, USA)	Kd: 3.5 μM	Decreased hepatic steatosis, improved lipid and glucose homeostasis, and inhibited cancer cell growth	43,129

CIC, citrate/isocitrate carrier; K_d, dissociation constant; K_i, inhibition constant.